Clinical Scorecard: The Tumor-Naive Cancer Blood Test

At a Glance

Key Highlights

• Identification of over 260,000 oncRNAs across 32 tumor types
• OncRNAs serve as a digital signature to distinguish cancer types
• Potential for simpler, earlier detection of persistent disease
• Association of oncRNA levels with treatment response and survival outcomes
• Tumor-naive strategy for liquid biopsy without prior tumor sequencing

Guideline-Based Recommendations

Diagnosis

• Utilize oncRNA barcodes for identifying tissue of origin in tumors

Management

• Consider oncRNA levels for monitoring treatment response in breast cancer

Monitoring & Follow-up

• Assess residual oncRNA burden for predicting long-term survival outcomes

Risks

• Potential challenges in applying circulating tumor DNA assays post-therapy

Patient & Prescribing Data

192 breast cancer patients treated with neoadjuvant chemotherapy

Changes in circulating oncRNA levels correlate with treatment response

Clinical Best Practices

• Incorporate oncRNA assays for post-treatment monitoring
• Use machine-learning classifiers for accurate cancer type identification
• Evaluate oncRNA levels for risk stratification after therapy

References

• Cell Reports Medicine Study